Evaluation of aquaporins in the cerebrospinal fluid in patients with idiopathic normal pressure hydrocephalus

• Published in: PloS one 2021-10, Vol.16 (10), p.e0258165-e0258165
• Main Authors: Hiraldo-González, Laura, Trillo-Contreras, José Luis, García-Miranda, Pablo, Pineda-Sánchez, Rocío, Ramírez-Lorca, Reposo, Rodrigo-Herrero, Silvia, Blanco, Magdalena Olivares, Oliver, María, Bernal, Maria, Franco-Macías, Emilio, Villadiego, Javier, Echevarría, Miriam
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Animal cognition; Aquaporin 1; Aquaporin 4; Aquaporins; Biology and Life Sciences; Biomarkers; Biophysics; Brain research; Care and treatment; Cerebrospinal fluid; Cognitive ability; Complications; Councils; Dementia; Dementia disorders; Demographic aspects; Demographic variables; Diagnosis; Health aspects; Health risks; Homeostasis; Hospitals; Hydrocephalus; Magnetic resonance imaging; Medicine and Health Sciences; Neurodegenerative diseases; Neurological diseases; Neurology; Neurosciences; Neurosurgery; Older people; Patients; Physiology; Proteins; Research and Analysis Methods; Risk analysis; Risk factors; Urinary incontinence
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0258165

Brain aquaporin 1 (AQP1) and AQP4 are involved in cerebrospinal fluid (CSF) homeostasis and might participate in the origin of hydrocephalus. Studies have shown alterations of perivascular AQP4 expression in idiopathic normal pressure hydrocephalus (iNPH) and Alzheimer’s disease (AD). Due to the overlapping of clinical signs between iNPH and certain neurological conditions, mainly AD, specific biomarkers might improve the diagnostic accuracy for iNPH. The goal of the present study was to analyze and quantify the presence of AQP1 and AQP4 in the CSF of patients with iNPH and AD to determine whether these proteins can be used as biomarkers of iNPH. We examined AQP1 and AQP4 protein levels in the CSF of 179 participants (88 women) classified into 5 groups: possible iNPH (81 participants), hydrocephalus associated with other neurological disorders (13 participants), AD (41 participants), non-AD dementia (32 participants) and healthy controls (12 participants). We recorded each participant’s demographic and clinical variables and indicated, when available in the clinical history, the record of cardiovascular and respiratory complications. An ELISA showed virtually no AQP content in the CSF. Information on the vascular risk factors (available for 61 patients) confirmed some type of vascular risk factor in 86% of the patients with possible iNPH and 58% of the patients with AD. In conclusion, the ELISA analysis showed insufficient sensitivity to detect the presence of AQP1 and AQP4 in CSF, ruling out the possible use of these proteins as biomarkers for diagnosing iNPH.